IL‐1β antagonism with the monoclonal antibody canakinumab has recently been shown to reduce recurrent events and IL‐6 levels in patients with established CAD in a large phase III clinical trial,6 thereby firmly establishing inflammatory cytokines as a therapeutic targets in CAD. This evidence concerns the gene IL1B and coronary artery disorder.